These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 39402023)
1. Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial. Chen S; Wang X; Yuan B; Peng J; Zhang Q; Yu W; Ge N; Weng Z; Huang J; Liu W; Wang X; Chen C Nat Commun; 2024 Oct; 15(1):8857. PubMed ID: 39402023 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens. Tu X; Zhang W; Li S; He Q; Li Y Eur J Med Res; 2024 Sep; 29(1):465. PubMed ID: 39294739 [TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Chen S; Zhang K; Liu W; Yu W Eur J Cancer; 2020 Jul; 134():90-98. PubMed ID: 32497895 [TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma. Zuo M; Cao Y; Yang Y; Zheng G; Li D; Shao H; Ma Q; Song P; An C; Li W Hepatol Int; 2024 Oct; 18(5):1486-1498. PubMed ID: 38961006 [TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study. Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511 [TBL] [Abstract][Full Text] [Related]
6. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388 [TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567 [TBL] [Abstract][Full Text] [Related]
8. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352 [TBL] [Abstract][Full Text] [Related]
9. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. Zhu LZ; Xu S; Qian HL World J Gastroenterol; 2018 Jun; 24(23):2501-2507. PubMed ID: 29930471 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study. Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230 [TBL] [Abstract][Full Text] [Related]
11. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion. Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095 [TBL] [Abstract][Full Text] [Related]
13. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis. Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693 [TBL] [Abstract][Full Text] [Related]
14. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis. Li Y; Liu W; Chen J; Chen Y; Guo J; Pang H; Zhang W; An C; Li C Cancer Med; 2024 Jan; 13(1):e6836. PubMed ID: 38196277 [TBL] [Abstract][Full Text] [Related]
15. Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study. Sun L; Hu Z; Xie W; Yang Z; Zeng H; Zhang Y; Chen M; Hu D; Zhou Z; Pan Y BMC Cancer; 2024 Sep; 24(1):1168. PubMed ID: 39300392 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575 [TBL] [Abstract][Full Text] [Related]
17. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Xu J; Shen J; Gu S; Zhang Y; Wu L; Wu J; Shao G; Zhang Y; Xu L; Yin T; Liu J; Ren Z; Xiong J; Mao X; Zhang L; Yang J; Li L; Chen X; Wang Z; Gu K; Chen X; Pan Z; Ma K; Zhou X; Yu Z; Li E; Yin G; Zhang X; Wang S; Wang Q Clin Cancer Res; 2021 Feb; 27(4):1003-1011. PubMed ID: 33087333 [TBL] [Abstract][Full Text] [Related]
18. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744 [TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013 [TBL] [Abstract][Full Text] [Related]
20. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. Guo JH; Zhang HY; Gao S; Zhang PJ; Li XT; Chen H; Wang XD; Zhu X World J Gastroenterol; 2017 Feb; 23(8):1406-1411. PubMed ID: 28293087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]